Genome-wide association and trans-ethnic meta-analysis for advanced diabetic kidney disease: Family Investigation of Nephropathy and Diabetes (FIND) by Iyengar, Sudha K. et al.
RESEARCH ARTICLE
Genome-Wide Association and Trans-ethnic
Meta-Analysis for Advanced Diabetic Kidney
Disease: Family Investigation of
Nephropathy and Diabetes (FIND)
Sudha K. Iyengar1☯*, John R. Sedor2,3☯*, Barry I. Freedman4☯*, W. H. Linda Kao5†,
Matthias Kretzler6, Benjamin J. Keller6, Hanna E. Abboud7†, Sharon G. Adler8, Lyle
G. Best9, Donald W. Bowden10, Allison Burlock6, Yii-Der Ida Chen11, Shelley A. Cole12,
Mary E. Comeau13, Jeffrey M. Curtis14, Jasmin Divers13, Christiane Drechsler15,
Ravi Duggirala12, Robert C. Elston1, Xiuqing Guo11, Huateng Huang16, Michael
Marcus Hoffmann17, Barbara V. Howard18, Eli Ipp19, Paul L. Kimmel20, Michael J. Klag21,
William C. Knowler14, Orly F. Kohn22, Tennille S. Leak6, David J. Leehey23, Man Li24,
Alka Malhotra14, Winfried März25, Viji Nair6, Robert G. Nelson14, Susanne B. Nicholas26,
Stephen J. O’Brien27, Madeleine V. Pahl28, Rulan S. Parekh29, Marcus G. Pezzolesi30,
Rebekah S. Rasooly31, Charles N. Rotimi32, Jerome I. Rotter11, Jeffrey R. Schelling2,
Michael F. Seldin33, Vallabh O. Shah34, AdamM. Smiles35, Michael W. Smith36, Kent
D. Taylor11, Farook Thameem37¤, Denyse P. Thornley-Brown38, Barbara J. Truitt1,
ChristophWanner39, E. Jennifer Weil14, Cheryl A. Winkler40, Philip G. Zager41, Robert
P. Igo, Jr1‡, Robert L. Hanson14‡, Carl D. Langefeld11‡, Family Investigation of
Nephropathy and Diabetes (FIND)¶
1 Department of Epidemiology & Biostatistics, CaseWestern Reserve University, Cleveland, Ohio,
United States of America, 2 Departments of Medicine, CaseWestern Reserve University, Cleveland, Ohio,
United States of America, 3 Departments of Physiology and Biophysics, CaseWestern Reserve University,
Cleveland, Ohio, United States of America, 4 Department of Internal Medicine, Section on Nephrology,
Wake Forest School of Medicine, Winston-Salem, North Carolina, United States of America, 5 Department
of Epidemiology and Medicine, John Hopkins University, Baltimore, Maryland, United States of America,
6 Department of Internal Medicine/Nephrology, University of Michigan, Ann Arbor, Michigan, United
States of America, 7 Department of Medicine/Nephrology, The University of Texas Health Science Center,
San Antonio, Texas, United States of America, 8 Department of Medicine, Division of Nephrology and
Hypertension, Harbor-UCLA Medical Center, Torrance, California, United States of America, 9 Missouri
Breaks Industries Research, Timber Lake, South Dakota, United States of America, 10 Department of
Biochemistry, Center for Human Genomics, Wake Forest School of Medicine, Winston-Salem, North
Carolina, United States of America, 11 The Institute for Translational Genomics and Population Sciences,
Harbor-UCLA Medical Center, Torrance, California, United States of America, 12 Department of Genetics,
Texas Biomedical Research Institute, San Antonio, Texas, United States of America, 13 Center for Public
Health Genomics and Department of Biostatistical Sciences, Division of Public Health Sciences, Wake
Forest School of Medicine, Winston-Salem, United States of America, 14 National Institutes of Diabetes and
Digestive and Kidney Diseases, National Institutes of Health, Phoenix, Arizona, United States of America,
15 University Hospital Würzburg, Renal Division and Comprehensive Heart Failure Center, Würzburg,
Germany, 16 Department of Ecology and Evolutionary Biology, University of Michigan, Ann Arbor, Michigan,
United States of America, 17 Department of Clinical Chemistry, University Medical Center, Freiburg,
Germany, 18 MedStar Health Research Institute, Hyattsville, Maryland, United States of America,
19 Department of Medicine, Section of Diabetes and Metabolism, Harbor-UCLA Medical Center, Torrance,
California, United States of America, 20 Division of Kidney, Urologic, and Hematologic Diseases, National
Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, Maryland, United States of America,
21 Johns Hopkins Bloomberg School of Public Health, Johns Hopkins School of Medicine, Baltimore,
Maryland, United States of America, 22 Department of Medicine, University of Chicago Medicine, Chicago,
Illinois, United States of America, 23 Department of Medicine, Loyola School of Medicine, Maywood, Illinois,
United States of America, 24 Department of Epidemiology, Johns Hopkins Bloomberg School of Public
Health, Baltimore, Maryland, United States of America, 25 Heidelberg University and Synlab Academy,
University of Graz, Graz, Austria, 26 Department of Medicine, University of California, Los Angeles,
Los Angeles, California, United States of America, 27 Theodosius Dobzhansky Center for Genome
PLOSGenetics | DOI:10.1371/journal.pgen.1005352 August 25, 2015 1 / 19
OPEN ACCESS
Citation: Iyengar SK, Sedor JR, Freedman BI, Kao
WHL, Kretzler M, Keller BJ, et al. (2015) Genome-
Wide Association and Trans-ethnic Meta-Analysis for
Advanced Diabetic Kidney Disease: Family
Investigation of Nephropathy and Diabetes (FIND).
PLoS Genet 11(8): e1005352. doi:10.1371/journal.
pgen.1005352
Editor: Scott M. Williams, Dartmouth College,
UNITED STATES
Received: November 24, 2014
Accepted: June 10, 2015
Published: August 25, 2015
Copyright: This is an open access article, free of all
copyright, and may be freely reproduced, distributed,
transmitted, modified, built upon, or otherwise used
by anyone for any lawful purpose. The work is made
available under the Creative Commons CC0 public
domain dedication.
Data Availability Statement: All FIND phenotype
and genotype files, except those for the American
Indian subjects, are available from the dbGAP
database (accession number phs000333.v1.p1). Data
for the American Indian subjects are not publically
available for privacy reasons. Interested researchers
who meet the criteria for access to the data can
contact: Robert Hanson ( rhanson@phx.niddk.nih.
gov) or Clifton Bogardus ( cbogardus@phx.niddk.nih.
gov).
Bioinformatics, St. Petersburg, Russia, and Oceanographic Center, Nova Southeastern University, Ft.
Lauderdale, Florida, United States of America, 28 Department of Medicine, University of California, Irvine,
Irvine, California, United States of America, 29 Departments of Paediatrics and Medicine, Hospital for Sick
Children, University Health Network and the University of Toronto, Toronto, Ontario, Canada, 30 Department
of Medicine, Joslin Diabetes Center, Harvard Medical School, Boston, Massachusetts, United States of
America, 31 National Institute of Diabetes and Digestive Disease, National Institutes of Health, Bethesda,
Maryland, United States of America, 32 Center for Research on Genomics and Global Health, Bethesda,
Maryland, United States of America, 33 Department of Biochemistry and Molecular Medicine, UC Davis
School of Medicine, Davis, California, United States of America, 34 Department of Biochemistry & Molecular
Biology, University of NewMexico, Albuquerque, NewMexico, United States of America, 35 Joslin Diabetes
Center, Section on Genetics and Epidemiology, Boston, Massachusetts, United States of America,
36 National Human Genome Research Institute, Rockville, Maryland, United States of America,
37 Department of Medicine, The University of Texas Health Science Center, San Antonio, Texas, United
States of America, 38 Nephrology, University of Alabama Birmingham, Birmingham, Alabama, United States
of America, 39 Department of Medicine, Division of Nephrology, University Hospital Würzburg, Würzburg,
Germany, 40 Center for Cancer Research, National Cancer Institute, Frederick, Maryland, United States of
America, 41 Department of Internal Medicine, University of NewMexico, Albuquerque, NewMexico, United
States of America
†Deceased.
☯ These authors contributed equally to this work.
¤ Current address: Department of Biochemistry, Faculty of Medicine, Kuwait University, Kuwait
‡RPI, RLH and CDL also contributed equally to this work.
¶ A complete listing of the FIND Consortium membership can be found in S1 Text.
* ski@case.edu (SKI); jrs4@case.edu (JRS); bfreedma@wakehealth.edu (BIF)
Abstract
Diabetic kidney disease (DKD) is the most common etiology of chronic kidney disease
(CKD) in the industrialized world and accounts for much of the excess mortality in patients
with diabetes mellitus. Approximately 45% of U.S. patients with incident end-stage kidney
disease (ESKD) have DKD. Independent of glycemic control, DKD aggregates in families
and has higher incidence rates in African, Mexican, and American Indian ancestral groups
relative to European populations. The Family Investigation of Nephropathy and Diabetes
(FIND) performed a genome-wide association study (GWAS) contrasting 6,197 unrelated
individuals with advanced DKD with healthy and diabetic individuals lacking nephropathy of
European American, African American, Mexican American, or American Indian ancestry. A
large-scale replication and trans-ethnic meta-analysis included 7,539 additional European
American, African American and American Indian DKD cases and non-nephropathy con-
trols. Within ethnic group meta-analysis of discovery GWAS and replication set results iden-
tified genome-wide significant evidence for association between DKD and rs12523822 on
chromosome 6q25.2 in American Indians (P = 5.74x10-9). The strongest signal of associa-
tion in the trans-ethnic meta-analysis was with a SNP in strong linkage disequilibrium with
rs12523822 (rs955333; P = 1.31x10-8), with directionally consistent results across ethnic
groups. These 6q25.2 SNPs are located between the SCAF8 and CNKSR3 genes, a region
with DKD relevant changes in gene expression and an eQTL with IPCEF1, a gene co-trans-
lated with CNKSR3. Several other SNPs demonstrated suggestive evidence of association
with DKD, within and across populations. These data identify a novel DKD susceptibility
locus with consistent directions of effect across diverse ancestral groups and provide insight
into the genetic architecture of DKD.
FIND GWAS in Diabetic Kidney Disease
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Author Summary
Type 2 diabetes is the most common cause of severe kidney disease worldwide and diabetic
kidney disease (DKD) associates with premature death. Individuals of non-European
ancestry have the highest burden of type 2 DKD; hence understanding the causes of DKD
remains critical to reducing health disparities. Family studies demonstrate that genes regu-
late the onset and progression of DKD; however, identifying these genes has proven to be
challenging. The Family Investigation of Diabetes and Nephropathy consortium (FIND)
recruited a large multi-ethnic collection of individuals with type 2 diabetes with and with-
out kidney disease in order to detect genes associated with DKD. FIND discovered and
replicated a DKD-associated genetic locus on human chromosome 6q25.2 (rs955333)
between the SCAF8 and CNKSR genes. Findings were supported by significantly different
expression of genes in this region from kidney tissue of subjects with, versus without
DKD. The present findings identify a novel kidney disease susceptibility locus in individu-
als with type 2 diabetes which is consistent across subjects of differing ancestries. In addi-
tion, FIND results provide a rich catalogue of genetic variation in DKD patients for future
research on the genetic architecture regulating this common and devastating disease.
Introduction
Diabetic kidney disease (DKD) is a devastating complication in patients with diabetes mellitus
(DM) and is associated with high risk for cardiovascular disease and death.[1,2] DKD is the
leading cause of end-stage kidney disease (ESKD) requiring renal replacement therapy in
developed nations; these procedures incur high healthcare costs with great personal, family
and societal burden.[3] The prevalence of DKD continues to rise in the United States in pro-
portion to the growing prevalence of DM. Unfortunately, intensification of glycemic, lipid and
blood pressure control have not dramatically impacted the prevalence of DKD.[3,4] Hypergly-
cemia alone is insufficient to cause DKD. Genetic factors appear critical in its pathogenesis
based upon variable incidence rates of DKD between population groups, aggregation of DKD-
associated ESKD in families, and the highly heritable nature of diabetic renal histologic
changes, estimated glomerular filtration rate (eGFR) and proteinuria.[5]
Genome-wide association studies (GWAS) have identified multiple loci for kidney function
and chronic kidney disease (CKD) in population- and community-based cohorts, primarily of
European ancestry.[6–10] However, CKD phenotypes in many studies included minimally to
moderately reduced eGFR, not fully reflective of the progressive forms of CKD seen in kidney
disease clinics. In early reports, published GWAS signals for DKD were equivocal, confounded
by small sample sizes and failure to consistently replicate. Recently, the GEnetics of Nephropa-
thy: an International Effort (GENIE) consortium identified genome-wide significant, replicated
signals in a meta-analysis of over 12,000 type 1 (T1) DM patients with DKD of European
ancestry.[9] Type 2 (T2) DM is far more prevalent than T1DM, accounting for 90% of cases
worldwide and for the majority of prevalent cases of DKD. Relative to European Americans
(EAs) with T2DM, African American (AA), American Indian (AI), and Mexican American
(MA) patients with T2DM are disproportionately affected by severe DKD,[3] yet under-repre-
sented in genetic analyses. Defining the underlying genetic architecture responsible for
advanced T2DM-associated kidney disease in multiple populations could provide critical
insights into pathogenesis and identify new molecular targets for therapy. We report the results
of a GWAS in AA, EA, MA, and AI patients with DKD enrolled in the National Institute of
Diabetes and Digestive and Kidney Diseases (NIDDK)-sponsored “Family Investigation of
FIND GWAS in Diabetic Kidney Disease
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Nephropathy and Diabetes” (FIND) [11] and the corresponding large replication study and
trans-ethnic meta-analysis.
Results and Discussion
Demographic characteristics of the Discovery and Find Large Replication study (FILR) samples
that met FIND phenotype qualifications and genotype quality control (QC) are summarized in
Table 1 and S1 Table. The proportion of females, age at ESKD or enrollment, hemoglobin A1c
and proportion with diabetic retinopathy (DR) varied by ancestry but was generally compara-
ble between the Discovery and FILR samples within a specific ethnic population. Phenotypic
differences among these populations and their genetic and DKD prevalence differences moti-
vated the meta-analysis approach.
The principal component (PC) analysis identified PCs that genetically partitioned the Dis-
covery sample into ancestry groups consistent with self-report. S1 Fig displays the two-dimen-
sional partitioning via PC analysis with the boundaries for inclusion into the GWAS analysis.
The logistic regression model that included the PCs as covariates reduced the inflation factor to
nominal levels and combined with the P-P plot show no evidence of a systematic inflation (S2
Fig). In the replication, the inflation factor was λ = 1.05 using 278 AIMs. If we scale to 1,000
cases and 1,000 controls this would be λ1000 = 1.017, an appropriate inflation factor for the rep-
lication study. S3 Fig provides a summary of the statistical power analyses for the race-specific
discovery, replication analysis, and meta-analyses. These calculations show that for risk-predis-
posing variants shared across ancestries the study has power>0.50 and 0.80 to detect odds
ratios (OR) on the order of 1.06 to 1.15 for a minor allele frequency (MAF) = 0.45 and 1.30 to
1.36 for a MAF = 0.05, respectively. Further, leveraging the differences in linkage disequilib-
rium (LD) among the four ancestries, the study is powered to potentially reduce the size of the
associated region via trans-ethnic mapping.
Trans-ethnic Meta-Analysis Associations
The only locus that reached genome wide significance for DKD in the trans-ethnic meta-analy-
sis encompassing all FIND Discovery and Replication samples was rs955333 on chromosome 6
(minimum p-value 1.31x10-8 [additive]; minimum p-value 9.02x10-11 [dominant]) (Table 2).
Fig 1 contains the Manhattan plot for the meta-analysis across all ancestries included in the
Discovery and Replication samples. Consistent directions of association were present in three
ethnic groups (only AA samples did not pass QC) and several supporting single nucleotide
polymorphisms (SNPs) were detected in the region (regional plot in Fig 2). This SNP lies
between the SR-like carboxyl-terminal domain associated factor 8 gene (SCAF8) and the
connector enhancer of KSR family of scaffold proteins gene (CNKSR3), suggesting a possible
role in transcription regulation. CNKSR3 is a direct mineralocorticoid receptor target gene
involved in regulation of the epithelial sodium channel (ENaC) on the apical membrane of
cells in the distal nephron.[12] CNKSR3 is highly expressed in the renal cortical collecting
duct and upregulated in response to physiologic aldosterone concentrations. ENaC precisely
regulates renal sodium absorption and plays important roles in maintenance of plasma volume
and blood pressure. Ziera et al. [12] suggested that CNKSR3, a PSD-95/DLG-1/ZO-1 (PDZ)
domain containing protein, inhibits the RAS/ERK signaling pathway, stimulating ENaC activ-
ity with enhanced renal sodium absorption. More recently, CNKSR3 was shown to function
as an aldosterone-induced scaffolding platform that orchestrated assembly of ENaC and its
regulators Nedd4-2, Raf-1 and SGK-1 and was essential for stimulation of ENaC function by
aldosterone.[13] Clinically, renin-angiotensin-aldosterone system (RAAS) blockade serves as
a mainstay of therapy for patients with DKD and other proteinuric kidney diseases.[14,15]
FIND GWAS in Diabetic Kidney Disease
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Table 1. Demographic characteristics of study populations.
African American †
FIND Samples FILR Samples Out of Study
DKD Case Diabetic
Control
DKD Case Diabetic
Control
Non-Diabetic
Control
Non-Diabetic
Control
N 633 277 N 950 50 1 1886
Female 347
(54.8%)
213 (76.9%) Female 520 (54.7%) 31 (62.0%) 1 (100%) 938 (49.7%)
Age, years 56.8 ± 11.9 59.5 ± 11.0 Age, years 59.9 ± 11.0 64.3 ± 12.9 45.4 ± 13.2
ESRD 581
(91.8%)
0 (0%) ESRD 930 (97.9%) 0 (0%) 0 (0%)
HbA1c, % 7.02 ± 1.79 7.83 ± 1.92 HbA1c, % 7.27 ± 1.90 8.41 ± 2.15 5.80 not available
DM duration, y 20.8 ± 10.8 17.8 ± 7.56 DM duration, y 19.4 ± 10.5 21.8 ± 8.39 - -
Retinopathy,
%
69.6% 14.2% Retinopathy,
%
75.4% 20.8% not available
American Indian
FIND Samples FILR Samples
DKD Case Diabetic
Control
DKD Case Diabetic
Control
Non-Diabetic
Control
N 538 319 N 471 340 486
Female 323
(60.0%)
238 (74.6%) Female 268 (56.9%) 248 (72.9%) 246 (50.6%)
Age, years 55.9 ± 12.8 53.4 ± 12.4 Age, years 52.1 ± 12.6 54.7 ± 12.2 50.5 ± 11.1
ESRD 369
(68.6%)
0 (0%) ESRD 58 (12.3%) 0(0%) 0(0%)
HbA1c, % 7.39 ± 2.14 7.72 ± 1.61 HbA1c, % 8.58 ± 2.46 8.18 ± 1.91
DM duration, y 21.8 ± 10.2 17.9 ± 7.30 DM duration, y 15.3 ± 10.5 17.9 ± 6.9
Retinopathy,
%
72.3% 8.0% Retinopathy,
%
48.7% 10.4% -
European Ancestry
FIND Samples FILR Samples Out of Study
DKD Case Diabetic
Control
DKD Case Diabetic
Control
Non-Diabetic
Control
Non-Diabetic
Control
N 342 404 N 582 205 23 2545
Female 165
(48.3%)
236 (58.4%) Female 265 (45.5%) 94 (45.9%) 6 (26.1%) 1094 (43.0%)
Age, years 63.9 ± 11.3 61.7 ± 9.30 Age, years 66.1 ± 11.0 65.2 ± 9.57 51.1 ± 17.0
ESRD 284
(83.0%)
0 (0%) ESRD 421 (72.3%) 0 (0%) 0 (0%) 0 (0%)
HbA1c, % 7.07 ± 1.75 7.53 ± 1.58 HbA1c, % 7.05 ± 1.50 6.94 ± 1.76 7.17 ± 1.00 not available
DM duration, y 21.8 ± 8.88 18.8 ± 8.94 DM duration, y 19.55 ± 10.6 17.0 ± 8.05 - not available
Retinopathy,
%
70.2% 9.4% Retinopathy,
%
64.5% 10.2% - not available
Mexican Ancestry
FIND Samples
DKD Case Diabetic
Control
N 779 594 N
Female 413
(53.0%)
414 (69.7%) Female
Age, years 59.2 ± 10.7 57.7 ± 9.83 Age, years
ESRD 552
(70.9%)
0 (0%) ESRD
(Continued)
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Inhibition of aldosterone may further limit renal fibrosis, independent of natriuretic effects.
[16,17] Hence, significant association between DKD and markers near CNKSR3 is consistent
with clinical trial data demonstrating that blockade of the renin angiotensin system or the aldo-
sterone receptor slows DKD progression. However, further experiments are needed to demon-
strate that the associated SNP regulates the pathogenesis of progressive DKD. Further studies
will be necessary to assess if the CNKSR3 regulates DKD pathogenesis indirectly by its effects
on ENaC activity or directly by promoting aldosterone-dependent fibrosis.
Less is known about the function of SCAF8, also known as RBM16. SCAF8 is a RNA matu-
ration factor recruited to the carboxy-terminal domain of RNA polymerase II in a phosphory-
lation-dependent manner.[18] It also is a target for ataxia telangiectasia mutated (ATM)
kinase, a crucial component of the DNA damage response required for DNA repair and cell
cycle control.[19] ATM kinase is associated with responsiveness of patients with DM to the
insulin sensitizer metformin in some but not all studies.[20,21] Thus, genes in the region of
rs955333 are suggestive of DKD-related pathogenesis.
GWAS loci identify elements that may regulate gene expression, and recent data indicate
GWAS associations are located in regions bounded by recombination hot spots near non-cod-
ing causal variants, which regulate transcription.[22,23] We next contrasted transcript abun-
dance of the genes within the megabase region centered on rs955333, TIAM2, SCAF8,
CNKSR3, IPCEF1 and OPRM1, in DKD and living donor kidney biopsies. DKD biopsies were
obtained from European and AI cohorts and were analyzed separately. All five genes show
Table 1. (Continued)
HbA1c, % 7.25 ± 1.75 8.28 ± 1.89 HbA1c, %
DM duration, y 19.8 ± 8.50 15.8 ± 6.07 DM duration, y
Retinopathy,
%
81.9% 17.0% Retinopathy,
%
† In the African American sample, we obtained out-of-study samples from Wake Forest University and Howard University (see Methods). Their
demographic characteristics are as follows: 931 DKD cases are 60.3% female, Age in years 61.6 ± 10.5, DM duration in years 19.7 ± 10.7; 92
Diabetic controls are all female, Age in years 55.1 ± 11.6, No Diabetes duration available; 1288 Non-Diabetic controls are 35.5% female, Age in
years 48.0 ± 12.4. FILR–FIND Large Replication study.
doi:10.1371/journal.pgen.1005352.t001
Table 2. Trans-ethnic meta-analysis GWAS results, across Discovery and Replication samples.
Discovery Replication Meta-Analysis
SNP Cytoband Position Gene RA OR 95% CI P-value Direction OR 95% CI P-value Direction OR 95% CI P-value *
rs955333 6q25.2 154947408 G 0.75 0.64–0.87 3.30E-04 ?—- 0.72 0.63–0.83 1.04E-05 ?— 0.73 0.66–0.81 1.31E-08 a
rs5750250 22q12.3 36708483 MYH9 G 1.39 1.23–1.57 2.56E-07 +??? 1.15 1.03–1.29 1.76E-02 +?? 1.27 1.16–1.38 7.70E-08 a
rs11107616 12q21.2 78364780 NAV3 C 1.42 1.20–1.69 2.55E-05 ?+++ 1.31 1.05–1.63 1.53E-02 ?+? 1.38 1.21–1.57 1.24E-06 a
rs136161 22q12.3 36657432 APOL1 G 1.52 1.26–1.85 7.30E-07 +?++ 1.09 0.88–1.34 3.97E-02 +-+ 1.27 1.10–1.46 1.91E-06 r
rs12285658 11q21 94723623 KDM4D G 0.55 0.33–0.93 1.75E-04 -??- 0.73 0.59–0.90 3.52E-03 -?? 0.62 0.46–0.85 2.00E-06 d
rs4879670 9p13.3 33205408 G 1.20 1.10–1.31 2.37E-05 ++-+ 1.11 1.03–1.20 1.01E-02 +++ 1.15 1.09–1.22 2.09E-06 a
rs11582609 1p31.1 83220656 A 0.76 0.66–0.87 4.55E-05 -+— 0.85 0.75–0.97 1.02E-02 —- 0.81 0.73–0.89 3.46E-06 d
rs1997066 10q25.1 106763563 SORCS3 C 0.59 0.46–0.76 2.30E-05 -?— 0.77 0.62–0.96 1.89E-02 -?- 0.68 0.57–0.80 4.28E-06 d
rs13259109 8q23.3 113115897 G 1.15 1.03–1.28 7.37E-03 ++++ 1.22 1.11–1.34 1.72E-04 +++ 1.19 1.11–1.27 4.58E-06 a
rs6432852 2q24.3 166754553 TTC21B G 0.84 0.77–0.92 3.63E-04 —— 0.87 0.80–0.94 3.51E-03 —- 0.85 0.80–0.91 5.18E-06 a
Direction: RA is risk allele. The odds ratio (OR) is presented for the risk allele, compared with the non-risk allele, for a given model. The FIND ancestry
groups are presented in the following order: AA-AI-EA-MA. A “+” or “-”indicates the direction of the effect in individuals of a speciﬁc ancestry. A “?” denotes
that the indicated SNP did not pass QC in that ancestry and the results were not included in the meta-analysis. *a, additive; r, recessive; d, dominant
doi:10.1371/journal.pgen.1005352.t002
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Fig 1. Manhattan plot of FIND GWASmeta-analysis associations across ancestries included in Discovery and Replication samples.
doi:10.1371/journal.pgen.1005352.g001
Fig 2. Zoom plot of the SCAF8 gene region (trans-ancestry meta-analysis across Discovery and Replication samples). Squares denote SNPs in the
Replication Study, Circles are SNPs that are only present in the GWAS, so the P-values shown reflect the GWAS Trans-Ancestry Meta-Analysis. The Ad-
Mixed American population in 1000 Genomes was used for LD information.
doi:10.1371/journal.pgen.1005352.g002
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statistically significant differential expression in at least one kidney tissue compartment of one
population. SCAF8 steady state mRNA levels show increased expression in DKD compared to
living donor biopsies in glomerular and tubulo-interstitial compartments of both populations
(S2B Table); TIAM2 and OPRM1 show glomerular-specific differential expression; IPCEF1 is
repressed in both tissue compartments of AI subjects; and CNKSR3 is increased in the tubulo-
interstitial compartment of AIs (S2B Table). Normalized tubulo-interstitial expression of
CNKSR3 correlated with urine albumin (r = 0.78, q = 0.0056) and urine albumin:creatinine
ratio (UACR) (r = 0.74, q = 0.0107). In addition, IPCEF1, located downstream of CNKSR3, has
been reported to be translated with CNKSR3 as one protein,[24] and has a tubulo-interstitial
expression quantitative trait locus (eQTL) (NM_001130699, rs249964, P = 2.34E-04) (S2A
Table). LD between this SNP and the sentinel variants in the region significantly associated
with DKD in the trans-ethnic (rs955333) and AI association analysis (rs12523822; see below)
is negligible (D’ = 0.43, r2 = 0.01 in AI). However, tubulo-interstitial expression of IPCEF1 in
kidney tissue from AIs was significantly correlated with the DKD phenotype UACR (r = -0.54,
q = 0.031). These studies were limited by the small number of available biopsies the narrow cri-
teria used to define the region of interest (see Methods). As proxies, disease-dependent differ-
ential gene expression and the rs249964 eQTL demonstrate DKD regulatory activity in the
locus. Significant results of eQTL and differential gene expression analyses for other loci in
Table 2 are also sown in S2A Table and S2B Table, respectively.
African American Associations
No SNP reached genome-wide significance (P<5x10-8) in the AA GWAS; however, a number
provided suggestive evidence for association with DKD (Table 3; S5A Table and S6A Table
summarize the top 200 SNP associations in the discovery GWAS and replication study, respec-
tively). The strongest associations were found within the apolipoprotein L1 (APOL1) and non-
muscle heavy chain 9 gene (MYH9) region on 22q (Table 2, Discovery + FILR meta-analysis:
rs5750250, P = 7.7x10-8; rs136161, P = 5.23x10-7). Since G1 and G2 variants of APOL1 are
strongly associated with non-diabetic nephropathy in AA patients,[25–27] the G1/G2 com-
pound risk was modeled under a recessive genetic model and these variants accounted for the
associations on 22q in Table 2 (rs5750250 P = 7.70x10-8, OR = 1.27; rs136161 P = 5.23x10-7,
OR = 1.36). Association with G1/G2 within APOL1 likely exists due to inclusion of non-FIND
AA cases with coincident DM and unrecognized non-diabetic kidney disease.[28] APOL1 was
not associated with T2D-ESKD in a logistic regression analysis adjusting for age, gender and
global ancestry restricted to FINDMALD and CHOICE (Choices for Healthy Outcomes In
Caring for End-stage renal disease) study cases meeting the original FIND DKD case definition
(rs73885319 P = 0.1098; rs71785313 P = 0.1182).[29]
Regions beyond 22q provided suggestive evidence of association in the AA Discovery
+ FILR meta-analysis including rs1298908 on 10q22 (OR = 1.36, P = 8.83x10-7) between
MAT1A and ANXA11, in a region dense with regulatory elements and transcription factors.
There was also an association on 3p26 (rs304029, OR = 1.26 P = 1.10x10-6) within inositol
1,4,5-trisphosphate receptor, type 1 (ITPR1), a gene involved in cerebellar and autoimmune
disorders but not renal involvement.[30] The genes in these other candidate regions (ANXA11,
MAT1A and ITPR1) also show statistically significant differential expression in at least one
population and compartment; as do IGSF22 near candidate rs11766496 on chromosome 11,
and TNFRSF19 near rs95107795 on chromosome 13. Other top AA associated regions in
Table 2 do not have clear connections to kidney disease. Since APOL1 association likely
reflected inclusion of non-FIND cases with non-diabetic nephropathy, a GWAS was re-com-
puted within AAs in the discovery sample, which only included subjects lacking two APOL1
FIND GWAS in Diabetic Kidney Disease
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risk variants. The top 200 associations from this GWAS are summarized in S7 Table. The cor-
relation between the–log10 (p-value) for GWAS with and with AA subjects with and without
two APOL1 risk variants is r = 0.82 (S4 Fig). The top association in this subset GWAS was
rs2780902 on 1p31 (OR = 0.52, P = 2.98x10-7) within Janus kinase 1 (JAK1), a member of the
protein-tyrosine kinases.[31] The ENCODE data shows that this SNP resides within a region
with numerous transcription factors and DNase I hypersensitivity sites. JAK1 is a widely
expressed membrane associated phosphoprotein and is involved in interferon transduction
pathway. This kinase links cytokine ligand binding to tyrosine phosphorylation of various
known signaling proteins and the signal transducers and activators of transcription (STATs).
Another interesting association among the top 10 associations is rs2596230 on 15q14
(OR = 1.56, P = 9.36x10-6) within ryanodine receptor 3 (RYR3).[32] The protein encoded by
RYR3 functions to release calcium from intercellular storage in many cellular processes and the
gene is expressed in the kidney. The closely related gene, RYR2, is associated with albuminuria.
[33] Our prior analyses of transcript expression in DKD biopsies provide additional support
for the associations. Both JAK1 and RYR3 (and RYR2) show differential expression that is
restricted to the European subjects with Stage III and Stage IV CKD. JAK1 expression is
increased in DKD in both compartments, while RYR3 and RYR2 are depressed in the glomeru-
lus.[34] We also recomputed the genome wide discovery and trans-ethnic meta-analysis
removing AA subjects with APOL1. The top 200 associations are summarized in S8 Table.
American Indian Associations
Several regions provided evidence of association with DKD in AIs (Table 3; S5B Table and
S6B Table summarize the top 200 SNP associations in the discovery GWAS and replication
study, respectively). The strongest association was with rs12523822 on 6q.25 in the SCAF8-
CNKSR3 gene region (OR = 0.57, P = 5.74x10-9). This SNP is in strong LD with rs955333, the
top hit in the trans-ethnic meta-analysis (r2 = 0.96 in AI unrelated controls); S5 Fig graphically
illustrates the extended linkage disequilibrium in this region in all but the AA samples. The A
allele at rs955333 is the ancestral allele and confers susceptibility to DKD (as the G allele has
OR<1 in Table 2); the A allele has a frequency of 0.76 in the American Indian samples and
0.85 in European American samples, but is nearly monomorphic in African American samples.
The allele frequencies are very similar in population-based samples: 0.85 in HapMap CEU,
1.00 in YRI, 0.77 in MEX and 0.76 in full-heritage American Indians from the southwestern
United States (R Hanson, personal communication). Thus, the high risk allele at this locus
does not appear to be Amerindian specific. The p-value for association in European Americans
is 0.0013 and 1.3x10-6 in American Indian, suggesting that the signal does not come entirely
from American Indians samples. Further fine-mapping or sequencing will be necessary to fully
characterize the association signal within and across ethnic groups. Another association that
approached genome-wide significance was rs13254600 (OR = 0.58, P = 5.54x10-8) on 8q24
within WD repeat domain 67 (WDR67). This gene is expressed in a wide variety of tissues,
including kidney, and may affect cellular membrane functions by regulating Rab GTPase activ-
ity.[35] TBC1D31 (WDR67) mRNA is increased in both compartments of kidney tissue from
AIs, but only in the glomerulus for European subjects with more advanced DKD.
Another SNP of interest is rs10019835 (OR = 0.70, 5.47x10-7) on 4q32 within guanylate
cyclase 1, soluble, alpha 3 (GUCY1A3); the protein encoded by GUCY1A3 serves as a receptor for
nitric oxide,[36] which through its role in endothelial function may be a mediator of DKD.[37]
GUCY1A3 is differentially expressed in both tissue compartments and both DKD biopsy cohorts,
and shows one of the strongest differences of all genes in candidate regions (especially among the
European subjects who have more advanced DKD) (S3A Table and S3B Table; S6 Fig). In
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addition, the candidate SNP rs10019835 has a tubulo-interstitial specific eQTL with the full-
length isoform ofGUCY1A3 (NM_000856, P = 4.97x10-4). The shortest isoform of the gene
(NM_001130687) has a glomerular eQTL with rs12504357 (P = 2.63x10-5), an intronic SNP that
is 5kb upstream of the associated variant. These two eQTL SNPs haveD’ = 1 in some popula-
tions, likely reflecting low allele frequencies in the reference populations. Integrin alpha 6
(ITGA6, rs13421350, 2q31, OR = 0.58, P = 5.54x10-8) is involved in cell adhesion and is expressed
in the kidney. The gene shows negative differential expression in Europeans with DKD, and it
has both glomerular and tubulo-interstitial eQTL. The glomerular eQTL is with the SNP
rs6758468 (P = 5.41x10-4), which is 143kb from the candidate; while the tubulo-interstitial
eQTL is with rs12469788 (P = 3.26x10-4), which is 5kb from the candidate withD’ = 1, but negli-
gible r2. Finally, rs10952362 on 7q36 near XRCC2 (rs10952362, OR = 1.91, P = 7.99x10-8), a gene
involved in DNA repair was strongly associated with DKD.[38] We find that XRCC2 is repressed
in the tubulo-interstitial kidney tissue from AIs.
European American Associations
EA subjects comprised the smallest group within FIND and power to detect variants associated
with DKD was limited (S3 Fig). None of the associations in the EA Discovery + FILR meta-
analysis had a p-value<10−5 (Table 3; S5C Table and S6C Table summarize the top 200 SNP
associations in the discovery GWAS and replication study, respectively).
Mexican American Associations
Several suggestive associations were identified in the MA Discovery GWAS (Table 3; S5D
Table summarizes the top 200 SNP associations in the GWAS). No replication cohort was
available to be genotyped in FILR, so only the Discovery GWAS and trans-ethnic meta-analysis
are reported (Tables 2 and 3). The strongest association was on 12q24 for rs7975752, located
~242 kb downstream of the mediator complex subunit 13-like (MED13L) gene (OR = 1.76,
P = 1.67 x 10−6). MED13L functions as a transcriptional coactivator for RNA polymerase II-
transcribed genes. While its functional significance in DKD is unclear, gene variants 4 Mb
downstream (rs614226) and upstream (rs653178) on 12q24 show genome-wide significant
association with ESKD [9] and CKD [39] in Europeans. We see that MED13L is repressed in
both compartments in kidney tissue from AIs but only in the glomerular transcriptome in the
European subjects. Association was observed between DKD and rs731565 (P = 4.06 x 10−6)
residing within an intronic region of the contactin-associated protein-like 2 (CNTNAP2) gene
on 7q36. SNP rs7805747, approximately 4 Mb downstream from rs731565 has been associated
with CKD in European populations [39] Finally, rs4849965, 1.2 Mb upstream of the SRY-
related HMG-box 11 (SOX11) gene on 2p25.2 trended toward association with DKD (OR 1.50,
95% CI 1.26–1.79; P = 6.18x10-6) and has previously been associated with CKD in Europeans.
[39] We find that absolute tubulo-interstitial expression of SOX11 in AIs is correlated with
ACR (r = 0.66, q = 0.029).
Conclusions
The current FIND GWAS comprises the largest genetic analysis for severe DKD based upon
risk for progression to ESKD in EA and high-risk non-European ethnic groups including
AAs, AIs, and MAs. As in other GWAS, results support a role for multiple DKD susceptibility
genes, each with weak effects. A number of the SNPs most strongly associated with DKD
had additional support from compartment-specific gene expression measures and eQTL analy-
sis obtained in European and American Indian populations. A novel chromosome 6q25.2
DKD locus was identified in AI samples; SNPs in this region had genome-wide significant
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association and consistent directions of effect in the meta-analysis across all ethnic groups.
Independent support for this region comes from an association with serum creatinine/eGFR in
a GWAS in East Asian populations (P = 2.6 x 10−5 at rs4870304) [40]. Strengths of the FIND
GWAS were the severe phenotype in cases, focus on DKD in T2D, and inclusion of non-Euro-
pean populations. The 6q25.2 locus requires fine mapping and additional replication in inde-
pendent sample sets of diabetic subjects with and without DKD that has sufficient power to
detect associated, common variants with moderate effect size. Once localized and replicated,
functional studies in animal and cell culture models will be necessary to discover the biological
mechanisms responsible for the association of DKD with the underlying genetic architecture.
As in other GWAS for complex disease, many previously identified DKD loci were not rep-
licated in the FIND analyses. The inconsistency between our data and published DKD GWAS
could reflect that FIND limited the DKD case group to subjects with ESKD and DKD with
heavy proteinuria felt to be at high risk for progression to ESKD. FIND did not include micro-
albuminuric participants as “cases” in the Discovery cohort, choosing instead to focus on
advanced nephropathy. However, some microalbuminuric participants with ACR<100 mg/g
were included in the replication analysis. Prior GWAS focused on European and Asian DKD
populations, often enriched for T1D-associated DKD. Genetic associations may not replicate
across other populations; for example, association of APOL1 variants with non-diabetic kidney
disease is limited to populations with recent African ancestry. Another possible interpretation
is the variants, which regulate DKD pathogenesis, are distinct for T1D and T2D, although a
meta-analysis including both T1D and T2D subjects may identify shared loci. Finally, the DKD
phenotype in the FIND GWAS relied on standard, stringent clinical criteria for advanced
DKD. This approach limited phenotypic heterogeneity but potentially minimized the utility of
cross-study comparisons. Although heavy proteinuria is a hallmark of DKD, recent analyses
suggest approximately one third of patients with diabetes and an eGFR<60 ml/min per 1.73
m2 had normal urinary protein excretion.[4] This would justify the focus of FIND on advanced
DKD. Although not the only DKD phenotype with a genetic component, several investigators
recently proposed using ESKD as the optimal DKD phenotype in genetic association studies.
[41,42] The availability of bio-samples from patients with advanced DKD is limited. Therefore,
entry criteria in the present replication cohorts were loosened to increase sample size; this
likely included a small number of participants with non-diabetic CKD (or DKD less likely to
progress to ESKD). The AA non-FIND cases used in our replication cohort appear to have
included individuals with DM and coincident focal segmental glomerulosclerosis (FSGS), an
effect addressed via partitioning based on APOL1 G1 and G2.[28] As in all GWAS, some non-
nephropathy controls may develop DKD. This effect would bias results toward the null making
it less likely to detect significant association.
FIND was well-powered to detect common risk variants with moderate effect sizes shared
across ethnic groups. It was also well powered to use differences in effect sizes to help localize
the region of association via transracial mapping. However, it was not powered to detect mod-
est ethnic-specific effects that are not shared with another ethnicity or gene-gene interactions.
Thus, these ethnic-specific scans provide important hypothesis generating results for subse-
quent meta-analyses, pathway enrichment analyses and hypothesis generation.
Materials and Methods
Ethics Statement
The FIND was completed in accordance with the principles of the Declaration of Helsinki.
Written informed consent was obtained from all participants. The Institutional Review
Board at each participating center (Case Western Reserve University, Cleveland, OH,
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Harbor-University of California Los Angeles Medical Center, Johns Hopkins University, Balti-
more, National Institute of Diabetes and Digestive and Kidney Diseases, Phoenix, AZ, Univer-
sity of California, Los Angeles, CA, University of New Mexico, Albuquerque, NM, University
of Texas Health Science Center at San Antonio, San Antonio, TX, Wake Forest School of Medi-
cine, Winston-Salem, NC) approved all procedures, and all study subjects provided written
informed consent. A certificate of confidentiality was filed at the National Institutes of Health.
Samples
Discovery cohorts. FIND is a multi-ancestry family study of severe DKD.[11] Index cases
had advanced DKD, likely to progress to ESKD based on clinical criteria, and at least one infor-
mative sibling with either DKD or long-standing DM without nephropathy. Detailed pheno-
type criteria for enrollment have been reported.[26,43,44] Index cases of AA, EA, MA and AI
ethnicity were included in the Discovery GWAS; all had DM duration>5 years and/or DR,
with UACR>1 g/g or ESKD. Unrelated controls had DM duration9 years, UACR<30 mg/g
(equating to overnight albumin excretion<20 mcg/min), and serum creatinine<1.6 mg/dl
([122 μmol/L] men) or<1.4 mg/dl ([107 μmol/L] women). In AA, EA and MA only unrelated
cases and controls were included; since AI participants were largely recruited from relatively
small communities all available cases and controls meeting criteria were included, regardless of
relationships.
Additional non-FIND-study DKD cases and controls (with and without DM) were geno-
typed to increase power (S1 Table). Non-FIND samples included unrelated DKD cases and
controls of self-reported African American ethnicity recruited at Wake Forest,[45] Case West-
ern Reserve [46] and Howard Universities;[47] unrelated cases and controls of EA ethnicity
recruited at Wake Forest [48] and Case Western Reserve;[49,50] cases and controls of AI eth-
nicity recruited at NIDDK-Phoenix; [51] and cases and controls of MA ethnicity recruited in
San Antonio and Los Angeles.[52]
Replication cohorts. The FIND Large Replication (FILR) Study was comprised of samples
independent from the Discovery cohorts. AA and EA replication cohorts were unrelated indi-
viduals recruited at Wake Forest, Johns Hopkins, Case Western Reserve and Harbor UCLA
Universities and out-of-study control data from the Genetic Association Information Network
(GAIN) consortium;[53] AI replication cohorts consisted of pedigree data from NIDDK-Phoe-
nix [51] and from the Dakota and Oklahoma centers of the Strong Heart Family Study.[54]
Replication cases had DM duration>5 years and/or DR, UACR0.3 g/g (equating to over-
night albumin excretion>200 mcg/min) and/or proteinuria>500 mg/day or ESKD. DM
controls had an eGFR>60 ml/min/1.73 m2, UACR<30 mg/g after 10 year DM duration or
UACR<100 mg/g after 15 year DM duration. GAIN study subjects with and without DM
were used as controls; no kidney function data were available for these individuals. GAIN sam-
ples were excluded for specific SNPs, if MAFs were inconsistent with those in FIND controls.
Additional MA subjects were not available for inclusion in FILR.
Samples analyzed. Based on ancestry, the FIND discovery GWAS samples included: (i)
AA: 1564 DKD cases (633 in FIND, 931 out of study), 369 controls with DM lacking nephropa-
thy (277 in FIND, 92 out of study) and 1,288 non-diabetic non-nephropathy controls (all out
of study); (ii) AI: 538 DKD cases, 319 controls with DM lacking nephropathy; (iii) EA: 342
DKD cases, 404 controls with DM lacking nephropathy; and (iv) MA: 779 DKD cases and 594
controls with DM lacking nephropathy. The FILR replication study included: (i) AA: 950 DKD
cases, 50 controls with DM lacking nephropathy and 1,887 non-diabetic non-nephropathy
controls; (ii) AI: 471 DKD cases, 340 controls with DM lacking nephropathy and 486 non-dia-
betic non-nephropathy controls and (iii) EA: 582 DKD cases, 205 controls with DM lacking
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nephropathy and 2,568 non-diabetic non-nephropathy controls. FILR samples were genotyped
at loci including the top associated SNPs from the Discovery GWAS, eQTL associations, litera-
ture-based candidate gene polymorphisms and ancestry informative markers (AIMs). S1 Table
delineates the sample sources in the Discovery GWAS and FILR, stratified by ancestry.
Genotyping and Statistical Methods
See Supplementary Methods (S1 Text).
SNP Selection for the Discovery and Replication Study
The DNA samples that comprise the Discovery cohorts, plus an additional 244 blind duplicates
were genotyped on the Affymetrix Genome-Wide Human 6.0 SNP array (see S1 Text Supple-
mental Methods for details). The FILR replication samples were genotyped for 3,937 SNPs
selected based on the strength of the statistical association from the Discovery GWAS. Addi-
tional SNPs were included based on the FIND eQTL association and candidate gene SNPs pre-
viously reported to be associated with DKD (see S1 Text Supplemental Methods for details).
Specifically, within each ancestry group, the SNPs with the strongest statistical evidence of
association were identified; a few additional SNPs from each region with supportive but weaker
evidence of association were also identified (i.e., associations due to LD but r2<0.95 with the
primary associated SNP). This redundancy was designed to limit the number of regions not
represented in the replication study due to genotyping failure. In total, 3,019 SNPs (821 AA,
790 AI, 608 EA, and 800 MA) were genotyped for FILR based solely on statistical association
with DKD within an ethnicity. The trans-ethnic meta-analysis of the discovery cohort identi-
fied another 436 SNPs nominally associated with DKD (p<0.0003). In addition, 482 SNPs
(121 AA, 133 AI, 122 EA, 14 MA, meta-analysis 92) were chosen with the smallest L2-norm
(i.e., Euclidean distance) of the–log10 (p-values) from GWAS and eQTL association analyses,
provided that p<0.01 from GWAS. Here, the L2-norm was defined relative to the maximum
of the–log10 (p-values) from the GWAS and eQTL and provides an ordering of the combined
evidence for eQTL and association with DKD. SNP associations in FILR were considered “rep-
licated” if both the association reached statistical significance and direction of the association
was consistent with the Discovery analysis. Finally, 278 AIMs were genotyped to allow for
adjustment of potential population substructure. Thus, FILR was designed as a replication
study and not a large-scale trans-ethnic fine-mapping study. Subsequent studies will complete
fine-mapping to localize associations.
Supporting Information
S1 Text. Supplementary Materials and Methods including a complete membership list of
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meta-analysis GWAS candidates (Table 2).
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S1 Fig. FIND: Principle components 1 versus 2. The principal component (PC) analysis iden-
tified PCs that genetically partitioned the Discovery sample into ancestry groups consistent
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S2 Fig. P-P plots of discovery GWAS. The logistic regression model, which included the PCs
as covariates, reduced the inflation factor to nominal levels and combined with the P-P plot
show no evidence of a systematic inflation.
(DOCX)
S3 Fig. Power curves. To estimate power, unmatched case and control subjects from Discovery
plus Replication [FILR] included: AA: 2514 cases, 3594 controls; AI: 1009 cases, 1145 controls;
EA: 924 cases, 3177 controls; MA: 779 cases, 594 controls (no Replication samples); and Meta-
analysis: 5226 cases, 8510 controls. The following assumptions were used for power analysis:
Additive Model; α = 1 x 10−6; and DM Population prevalence kp = 0.30.
(TIFF)
S4 Fig. Correlation between-log10(p-value) in the discovery AA GWAS including and
excluding subjects with APOL1 risk genotypes. The correlation between the–log10(p-value)
for GWAS with and with AA subjects with and without two APOL1 risk variants is r = 0.82.
(TIFF)
S5 Fig. Ethnic-specific linkage disequilibrium patterns on 6q25.2. The SCAF8-CNKSR3
region shows extended linkage disequilibriums in all ethnicities but AA.
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S6 Fig. Plot of GUCY1A3 expression levels (log2 transformed) against variant
rs10019835 genotypes showing effect indicated by eQTL in glomerulus but not the
FIND GWAS in Diabetic Kidney Disease
PLOS Genetics | DOI:10.1371/journal.pgen.1005352 August 25, 2015 15 / 19
tubulo-interstitium/cortex compartment in American Indian participants. The full-
length isoform NM_000856 has a tissue-specific tubulo-interstitial eQTL with AI GWAS
candidate rs10019835 (P = 4.97 x 10−4, glomerulus not significant at p > 0.00024), and
short isoform NM_001130687 having a glomerular eQTL with intronic SNP rs12504357
(P = 2.63 x 10−5, tubulo-interstitium not significant at p>0.05). Both isoforms satisfy the test
for expression in both tissues.
(TIFF)
Acknowledgments
The FIND investigators dedicate this work to our dear friends and colleagues Wen Hong Linda
Kao, Hanna Abboud, Nedal Arar, Mohammed Saad and Jane Olson. You all left us far too
soon, but will forever remain in our hearts. We also thank all FIND participants and study
staff, who made this project possible. Computing resources was provided in part by the Wake
Forest Center for Public Health Genomics.
Author Contributions
Conceived and designed the experiments: SKI JRSe BIF WHLKMK BJK HEA SGA RCE PLK
MJKWCK RGN SBNMVP RSP RSR JIR JRSc MFS MWS FT DPTB CAW PGZ RPI RLH
CDL. Performed the experiments: SKI JRSe BIF WHLKMK BJK HEA SGAMECMJKWCK
OFK DJL ML AM VN RGN SBNMVP RSP JIR JRSc MFS VOS MWS KDT FT DPTB CAW
PGZ RPI RLH CDL. Analyzed the data: SKI JRSe BIF WHLKMK BJK MECML VN RPI RLH
CDL. Contributed reagents/materials/analysis tools: SKI BIF JRSe WHLKMK BJK HEA SGA
LGB DWB AB YDIC SACMEC JMC JD CD RD RCE XG HHMMH BVH EI PLKMJKWCK
OFK TSL DJL ML AMWMVN RGN SBN SJO MVP RSP MGP RSR CNR JIR JRSc MFS VOS
AMSMWS KDT FT DPTB BJT CW EJW CAW PGZ RPI RLH CDL. Wrote the paper: SKI
JRSe BIF MK BJK RPI RLH CDL.
References
1. Ninomiya T, Perkovic V, de Galan BE, Zoungas S, Pillai A et al. (2009) Albuminuria and kidney function
independently predict cardiovascular and renal outcomes in diabetes. J Am Soc Nephrol 20: 1813–
1821. doi: 10.1681/ASN.2008121270 PMID: 19443635
2. Berhane AM,Weil EJ, Knowler WC, Nelson RG, Hanson RL (2011) Albuminuria and estimated glomer-
ular filtration rate as predictors of diabetic end-stage renal disease and death. Clin J Am Soc Nephrol
6: 2444–2451. doi: 10.2215/CJN.00580111 PMID: 21852671
3. [Anonymous] (2012) U.S. Renal Data System, USRDS 2012 Annual Data Report, Vol 1: Atlas of
Chronic Kidney Disease and End-Stage Renal Disease in the United States, National Institutes of
Health, National Institute of Diabetes and Digestive and Kidney Diseases.
4. de Boer I, Rue TC, Hall YN, Heagerty PJ, Weiss NS et al. (2011) Temporal trends in the prevalence of
diabetic kidney disease in the United States. JAMA 305: 2532–2539. doi: 10.1001/jama.2011.861
PMID: 21693741
5. Freedman BI, BostromM, Daeihagh P, Bowden DW (2007) Genetic factors in diabetic nephropathy.
Clin J Am Soc Nephrol 2: 1306–1316. PMID: 17942768
6. Pezzolesi MG, Poznik GD, Mychaleckyj JC, Paterson AD, Barati MT et al. (2009) Genome-wide associ-
ation scan for diabetic nephropathy susceptibility genes in type 1 diabetes. Diabetes 58(6): 1403–
1410. doi: 10.2337/db08-1514 PMID: 19252134
7. Maeda S, Kobayashi MA, Araki S, Babazono T, Freedman BI et al. (2010) A single nucleotide polymor-
phism within the acetyl-coenzyme A carboxylase beta gene is associated with proteinuria in patients
with type 2 diabetes. PLoS Genet 6: e1000842. doi: 10.1371/journal.pgen.1000842 PMID: 20168990
8. Pezzolesi MG, Poznik GD, Skupien J, Smiles AM, Mychaleckyj JC et al. (2011) An intergenic region on
chromosome 13q33.3 is associated with the susceptibility to kidney disease in type 1 and 2 diabetes.
Kidney Int 80: 105–111. doi: 10.1038/ki.2011.64 PMID: 21412220
FIND GWAS in Diabetic Kidney Disease
PLOS Genetics | DOI:10.1371/journal.pgen.1005352 August 25, 2015 16 / 19
9. Sandholm N, Salem RM, McKnight AJ, Brennan EP, Forsblom C et al. (2012) New susceptibility loci
associated with kidney disease in type 1 diabetes. PLoS Genet 8: e1002921. doi: 10.1371/journal.
pgen.1002921 PMID: 23028342
10. Sandholm N, McKnight AJ, Salem RM, Brennan EP, Forsblom C et al. (2013) Chromosome 2q31.1
associates with ESRD in women with type 1 diabetes. J Am Soc Nephrol 24: 1537–1543. doi: 10.1681/
ASN.2012111122 PMID: 24029427
11. Knowler WC, Coresh J, Elston RC, Freedman BI, Iyengar SK et al. (2005) The Family Investigation of
Nephropathy and Diabetes (FIND): design and methods. J Diabetes Complications 19: 1–9. PMID:
15642484
12. Ziera T, Irlbacher H, FrommA, Latouche C, Krug SM et al. (2009) Cnksr3 is a direct mineralocorticoid
receptor target gene and plays a key role in the regulation of the epithelial sodium channel. FASEB J
23: 3936–3946. doi: 10.1096/fj.09-134759 PMID: 19567370
13. Soundararajan R, Ziera T, Koo E, Ling K, Wang J et al. (2012) Scaffold protein connector enhancer of
kinase suppressor of Ras isoform 3 (CNK3) coordinates assembly of a multiprotein epithelial sodium
channel (ENaC)-regulatory complex. J Biol Chem 287: 33014–33025. PMID: 22851176
14. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD (1993) The effect of angiotensin-converting-enzyme inhi-
bition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 329(20): 1456–1462.
PMID: 8413456
15. Brenner BM, Cooper ME, de ZD, KeaneWF, MitchWE et al. (2001) Effects of losartan on renal and car-
diovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 20; 345(12):
861–869. PMID: 11565518
16. Bertocchio JP, Warnock DG, Jaisser F (2011) Mineralocorticoid receptor activation and blockade: an
emerging paradigm in chronic kidney disease. Kidney Int 79: 1051–1060. doi: 10.1038/ki.2011.48
PMID: 21412221
17. Rubin MF, Townsend RR (2009) Aldosterone blockade in diabetic nephropathy: relative risks and
potential promise. J Am Soc Nephrol 20: 2487–2489. doi: 10.1681/ASN.2009101036 PMID: 19875814
18. Becker R, Loll B, Meinhart A (2008) Snapshots of the RNA processing factor SCAF8 bound to different
phosphorylated forms of the carboxyl-terminal domain of RNA polymerase II. J Biol Chem 283: 22659–
22669. doi: 10.1074/jbc.M803540200 PMID: 18550522
19. Matsuoka S, Ballif BA, Smogorzewska A, McDonald ER III, Hurov KE et al. (2007) ATM and ATR sub-
strate analysis reveals extensive protein networks responsive to DNA damage. Science 316: 1160–
1166. PMID: 17525332
20. Zhou K, Bellenguez C, Spencer CC, Bennett AJ, Coleman RL et al. (2011) Common variants near ATM
are associated with glycemic response to metformin in type 2 diabetes. Nat Genet 43: 117–120. doi:
10.1038/ng.735 PMID: 21186350
21. Florez JC, Jablonski KA, Taylor A, Mather K, Horton E et al. (2012) The C allele of ATM rs11212617
does not associate with metformin response in the Diabetes Prevention Program. Diabetes Care 35:
1864–1867. PMID: 22751958
22. Green ED, Guyer MS (2011) Charting a course for genomic medicine from base pairs to bedside.
Nature 470: 204–213. doi: 10.1038/nature09764 PMID: 21307933
23. Lango AH, Estrada K, Lettre G, Berndt SI, Weedon MN et al. (2010) Hundreds of variants clustered in
genomic loci and biological pathways affect human height. Nature 467: 832–838. doi: 10.1038/
nature09410 PMID: 20881960
24. Attar MA, Salem JC, Pursel HS, Santy LC (2012) CNK3 and IPCEF1 produce a single protein that is
required for HGF dependent Arf6 activation and migration. Exp Cell Res 318: 228–237. doi: 10.1016/j.
yexcr.2011.10.018 PMID: 22085542
25. Kopp JB, Smith MW, Nelson GW, Johnson RC, Freedman BI et al. (2008) MYH9 is a major-effect risk
gene for focal segmental glomerulosclerosis. Nat Genet 40: 1175–1184. doi: 10.1038/ng.226 PMID:
18794856
26. KaoWH, Klag MJ, Meoni LA, Reich D, Berthier-Schaad Y et al. (2008) MYH9 is associated with nondia-
betic end-stage renal disease in African Americans. Nat Genet 40: 1185–1192. doi: 10.1038/ng.232
PMID: 18794854
27. Genovese G, Friedman DJ, Ross MD, Lecordier L, Uzureau P et al. (2010) Association of trypanolytic
ApoL1 variants with kidney disease in African Americans. Science 329: 841–845. doi: 10.1126/
science.1193032 PMID: 20647424
28. Freedman BI, Langefeld CD, Lu L, Divers J, ComeauME et al. (2011) Differential Effects of MYH9 and
APOL1 Risk Variants on FRMD3 Association with Diabetic ESRD in African Americans. PLoS Genet
7: e1002150. doi: 10.1371/journal.pgen.1002150 PMID: 21698141
FIND GWAS in Diabetic Kidney Disease
PLOS Genetics | DOI:10.1371/journal.pgen.1005352 August 25, 2015 17 / 19
29. KaoWH (2012) Diabetic Nephropathy Fails to Associate with the APOL1/MYH9 Locus or Type 2 Diabe-
tes Mellitus Susceptibility Genes: The Family Investigation of Nephropathy and Diabetes (FIND) Con-
sortium. J Am Soc Nephol 23: 249A.
30. Yamada N, Makino Y, Clark RA, Pearson DW, Mattei MG et al. (1994) Human inositol 1,4,5-trispho-
sphate type-1 receptor, InsP3R1: structure, function, regulation of expression and chromosomal locali-
zation. Biochem J 302 (Pt 3): 781–790. PMID: 7945203
31. Wilks AF, Harpur AG, Kurban RR, Ralph SJ, Zurcher G et al. (1991) Two novel protein-tyrosine
kinases, each with a second phosphotransferase-related catalytic domain, define a new class of protein
kinase. Mol Cell Biol 11: 2057–2065. PMID: 1848670
32. Marks AR, Tempst P, Hwang KS, TaubmanMB, Inui M et al. (1989) Molecular cloning and characteri-
zation of the ryanodine receptor/junctional channel complex cDNA from skeletal muscle sarcoplasmic
reticulum. Proc Natl Acad Sci U S A 86: 8683–8687. PMID: 2813419
33. Hwang SJ, Yang Q, Meigs JB, Pearce EN, Fox CS (2007) A genome-wide association for kidney func-
tion and endocrine-related traits in the NHLBI's Framingham Heart Study. BMCMed Genet 19; 8 Suppl
1: S10. PMID: 17903292
34. Berthier CC, Zhang H, Schin M, Henger A, Nelson RG et al. (2009) Enhanced expression of Janus
kinase-signal transducer and activator of transcription pathway members in human diabetic nephropa-
thy. Diabetes 58: 469–477. doi: 10.2337/db08-1328 PMID: 19017763
35. Stenmark H, Olkkonen VM (2001) The Rab GTPase family. Genome Biol 2: REVIEWS3007.
36. Zabel U, Weeger M, La M, Schmidt HH (1998) Human soluble guanylate cyclase: functional expression
and revised isoenzyme family. Biochem J 335 (Pt 1): 51–57. PMID: 9742212
37. Prabhakar SS (2004) Role of nitric oxide in diabetic nephropathy. Semin Nephrol 24: 333–344. PMID:
15252773
38. Thacker J, Tambini CE, Simpson PJ, Tsui LC, Scherer SW (1995) Localization to chromosome 7q36.1
of the human XRCC2 gene, determining sensitivity to DNA-damaging agents. HumMol Genet 4: 113–
120. PMID: 7711722
39. Kottgen A, Pattaro C, Boger CA, Fuchsberger C, Olden M et al. (2010) New loci associated with kidney
function and chronic kidney disease. Nat Genet 42: 376–384. doi: 10.1038/ng.568 PMID: 20383146
40. Okada Y, Sim X, Go MJ, Wu JY, Gu D et al. (2012) Meta-analysis identifies multiple loci associated with
kidney function-related traits in east Asian populations. Nat Genet 44: 904–909. doi: 10.1038/ng.2352
PMID: 22797727
41. Bowden DW, Freedman BI (2012) The challenging search for diabetic nephropathy genes. Diabetes
61: 1923–1924. doi: 10.2337/db12-0596 PMID: 22826311
42. Pezzolesi MG, Krolewski AS (2013) Diabetic nephropathy: is ESRD its only heritable phenotype? J Am
Soc Nephrol 24: 1505–1507. doi: 10.1681/ASN.2013070769 PMID: 24029425
43. Iyengar SK, Abboud HE, Goddard KA, Saad MF, Adler SG et al. (2007) Genome-wide scans for dia-
betic nephropathy and albuminuria in multiethnic populations: the family investigation of nephropathy
and diabetes (FIND). Diabetes 56: 1577–1585. PMID: 17363742
44. Schelling JR, Abboud HE, Nicholas SB, Pahl MV, Sedor JR et al. (2008) Genome-wide scan for esti-
mated glomerular filtration rate in multi-ethnic diabetic populations: the Family Investigation of Nephrop-
athy and Diabetes (FIND). Diabetes 57(1): 235–243. PMID: 18003762
45. McDonough CW, Palmer ND, Hicks PJ, Roh BH, An SS et al. (2011) A genome-wide association study
for diabetic nephropathy genes in African Americans. Kidney Int 79: 563–572. doi: 10.1038/ki.2010.
467 PMID: 21150874
46. Iyengar SK, Fox KA, Schachere M, Manzoor F, Slaughter ME et al. (2003) Linkage analysis of candi-
date loci in end-stage renal disease due to diabetic nephropathy. J Am Soc Nephol 14: S195–S201.
47. Ramos E, Chen G, Shriner D, Doumatey A, Gerry NP et al. (2011) Replication of genome-wide associa-
tion studies (GWAS) loci for fasting plasma glucose in African-Americans. Diabetologia 54: 783–788.
doi: 10.1007/s00125-010-2002-7 PMID: 21188353
48. Cooke JN, BostromMA, Hicks PJ, Ng MC, Hellwege JN et al. (2012) Polymorphisms in MYH9 are
associated with diabetic nephropathy in European Americans. Nephrol Dial Transplant 27: 1505–
1511. doi: 10.1093/ndt/gfr522 PMID: 21968013
49. Iyengar SK, Fox KA, Schachere M, Manzoor F, Slaughter ME et al. (2003) Linkage analysis of candi-
date loci for end-stage renal disease due to diabetic nephropathy. J Am Soc Nephrol 14: S195–S201.
PMID: 12819328
50. Gunzler D, Bleyer AJ, Thomas RL, Brien O, Russell GB et al. (2013) Diabetic nephropathy in a sibling
and albuminuria predict early GFR decline: a prospective cohort study. BMC Nephrol 14: 124. doi: 10.
1186/1471-2369-14-124 PMID: 23773264
FIND GWAS in Diabetic Kidney Disease
PLOS Genetics | DOI:10.1371/journal.pgen.1005352 August 25, 2015 18 / 19
51. Pavkov ME, Knowler WC, Hanson RL, Williams DE, Lemley KV et al. (2013) Comparison of serum
cystatin C, serum creatinine, measured GFR, and estimated GFR to assess the risk of kidney failure in
American Indians with diabetic nephropathy. Am J Kidney Dis 62: 33–41. doi: 10.1053/j.ajkd.2012.11.
044 PMID: 23347458
52. Thameem F, Puppala S, Lehman DM, Stern MP, Blangero J et al. (2010) The Ser(326)Cys Polymor-
phism of 8-Oxoguanine Glycosylase 1 (OGG1) Is Associated with Type 2 Diabetes in Mexican Ameri-
cans. Hum Hered 70: 97–101. doi: 10.1159/000291964 PMID: 20606456
53. Manolio TA, Rodriguez LL, Brooks L, Abecasis G, Ballinger D et al. (2007) Newmodels of collaboration
in genome-wide association studies: the Genetic Association Information Network. Nat Genet 39:
1045–1051. PMID: 17728769
54. Franceschini N, Haack K, Almasy L, Laston S, Lee ET et al. (2014) Generalization of associations of
kidney-related genetic loci to American Indians. Clin J Am Soc Nephrol 9: 150–158. doi: 10.2215/CJN.
02300213 PMID: 24311711
FIND GWAS in Diabetic Kidney Disease
PLOS Genetics | DOI:10.1371/journal.pgen.1005352 August 25, 2015 19 / 19
